Merck and Pfizer will begin co-promoting Xalkori in the U.S., Canada, Japan and five European Union countries: France, Germany, Italy, Spain and the U.K.In the U.S. and Canada, Xalkori will be co-promoted by EMD Serono, the US and Canadian biopharmaceutical businesses of Merck.
Rubicon Genomics Inc. extended its clinical supply agreement with Agendia for use of its TransPLEX whole genome RNA amplification technology.
Intrexon Corp. signed a cooperative research and development agreement with NCI for the development of adoptive T cell therapies utilizing the RheoSwitch Therapeutic System platform for the treatment of solid tumor malignancies.
Intrexon Corporation and Merck Serono, the biopharmaceutical arm of Merck KGaA, announced an exclusive collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell cancer therapies.
Merck and Syndax Pharmaceuticals Inc. entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Syndax's entinostat, an investigational epigenetic therapy, with Merck's Keytruda (pembrolizumab).
Eli Lilly and Co. and OncoMed Pharmaceuticals Inc. entered into an agreement to evaluate the combination of demcizumab and Alimta (pemetrexed for injection) in lung cancer.
MD Anderson Cancer Center and Astellas Pharma Inc. signed an option agreement to research and develop a new treatment for patients with acute myeloid leukemia.
FDA approved Jadenu (deferasirox) tablets, a new oral formulation of Exjade (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes in patients 10 years of age and older.
FDA approved a label update for Zytiga (abiraterone acetate) plus prednisone to include overall survival results in chemotherapy-naive men with metastatic castration-resistant prostate cancer.
FDA granted Priority Review to Kyprolis (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The agency also accepted the drug's supplemental new drug application designed to support the conversion of accelerated approval to full approval and expand the current Kyprolis indication. FDA set a target action date of July 26.
